PMID- 22448225
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20240317
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 3
DP  - 2012
TI  - A common HLA-DPA1 variant is associated with hepatitis B virus infection but 
      fails to distinguish active from inactive Caucasian carriers.
PG  - e32605
LID - 10.1371/journal.pone.0032605 [doi]
LID - e32605
AB  - BACKGROUND AND AIMS: Chronic infection with the hepatitis B virus (HBV) is a 
      major health issue worldwide. Recently, single nucleotide polymorphisms (SNPs) 
      within the human leukocyte antigen (HLA)-DP locus were identified to be 
      associated with HBV infection in Asian populations. Most significant associations 
      were observed for the A alleles of HLA-DPA1 rs3077 and HLA-DPB1 rs9277535, which 
      conferred a decreased risk for HBV infection. We assessed the implications of 
      these variants for HBV infection in Caucasians. METHODS: Two HLA-DP gene variants 
      (rs3077 and rs9277535) were analyzed for associations with persistent HBV 
      infection and with different clinical outcomes, i.e., inactive HBsAg carrier 
      status versus progressive chronic HBV (CHB) infection in Caucasian patients 
      (n = 201) and HBsAg negative controls (n = 235). RESULTS: The HLA-DPA1 rs3077 C 
      allele was significantly associated with HBV infection (odds ratio, OR = 5.1, 95% 
      confidence interval, CI: 1.9-13.7; p = 0.00093). However, no significant 
      association was seen for rs3077 with progressive CHB infection versus inactive 
      HBsAg carrier status (OR = 2.7, 95% CI: 0.6-11.1; p = 0.31). In contrast, 
      HLA-DPB1 rs9277535 was not associated with HBV infection in Caucasians (OR = 0.8, 
      95% CI: 0.4-1.9; p = 1). CONCLUSIONS: A highly significant association of 
      HLA-DPA1 rs3077 with HBV infection was observed in Caucasians. However, as a 
      differentiation between different clinical courses of HBV infection was not 
      possible, knowledge of the HLA-DPA1 genotype cannot be translated into 
      personalized anti-HBV therapy approaches.
FAU - Vermehren, Johannes
AU  - Vermehren J
AD  - pharmazentrum frankfurt/ZAFES, Institut fur Klinische Pharmakologie, Klinikum der 
      J. W. Goethe Universitat, Frankfurt am Main, Germany.
FAU - Lotsch, Jorn
AU  - Lotsch J
FAU - Susser, Simone
AU  - Susser S
FAU - Wicker, Sabine
AU  - Wicker S
FAU - Berger, Annemarie
AU  - Berger A
FAU - Zeuzem, Stefan
AU  - Zeuzem S
FAU - Sarrazin, Christoph
AU  - Sarrazin C
FAU - Doehring, Alexandra
AU  - Doehring A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120320
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA, Viral)
RN  - 0 (HLA-DP alpha-Chains)
RN  - 0 (HLA-DPA1 antigen)
RN  - 0 (Hepatitis B Surface Antigens)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Asian People/*genetics
MH  - Case-Control Studies
MH  - DNA, Viral/genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA-DP alpha-Chains/*genetics
MH  - Haplotypes
MH  - Hepatitis B/*genetics/immunology/*virology
MH  - Hepatitis B Surface Antigens/metabolism
MH  - Hepatitis B virus/*genetics/immunology
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - White People/*genetics
PMC - PMC3308944
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/03/27 06:00
MHDA- 2012/08/21 06:00
PMCR- 2012/03/20
CRDT- 2012/03/27 06:00
PHST- 2011/11/21 00:00 [received]
PHST- 2012/01/28 00:00 [accepted]
PHST- 2012/03/27 06:00 [entrez]
PHST- 2012/03/27 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
PHST- 2012/03/20 00:00 [pmc-release]
AID - PONE-D-11-23768 [pii]
AID - 10.1371/journal.pone.0032605 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(3):e32605. doi: 10.1371/journal.pone.0032605. Epub 2012 Mar 20.